Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Depreciation & Amortization (CF) (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 2.27% year-over-year to $1.9 million, compared with a TTM value of $7.6 million through Dec 2025, up 5.09%, and an annual FY2025 reading of $7.6 million, up 5.09% over the prior year.
  • Depreciation & Amortization (CF) was $1.9 million for Q4 2025 at Cytek Biosciences, down from $1.9 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.9 million in Q3 2025 and bottomed at $72000.0 in Q3 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $1.2 million, with a median of $1.6 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) crashed 61.9% in 2022, then surged 2354.17% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $685000.0 in 2021, then increased by 11.09% to $761000.0 in 2022, then skyrocketed by 114.32% to $1.6 million in 2023, then grew by 13.67% to $1.9 million in 2024, then grew by 2.27% to $1.9 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CTKB at $1.9 million in Q4 2025, $1.9 million in Q3 2025, and $1.9 million in Q2 2025.